Vernalis and Servier reach first oncology milestone
This article was originally published in Scrip
Executive Summary
Vernalisand the privately held French pharmaceutical company Servierhave achieved the first milestone in their three-year oncology drug discovery collaboration that was signed in May last year. The milestone, which will see Servier pay Vernalis $500,000, marks the solving of the novel crystal structure of an undisclosed oncology target. As part of the joint research programme Servier funds Vernalis's scientists and applies Vernalis's structure-based discovery capabilities to two oncology targets involved in protein-protein interactions.